Semaglutide improves heart failure outcomes and reduces cardiovascular events in obese patients with HFpEF, establishing GLP-1 peptide therapy as a novel treatment strategy targeting the obesity phenotype of heart failure.
Phenotype-targeted HF therapySTEP HFpEF demonstrated that targeting obesity specifically with semaglutide significantly improved outcomes in obese heart failure patients — a first for HFpEF treatment
What the researchers found
The STEP HFpEF trial demonstrated that semaglutide significantly improved multiple clinical outcomes in obese HFpEF patients with substantial weight loss. The SELECT trial showed significant reduction in cardiovascular and heart failure events in non-diabetic obese patients. Both trials support obesity-targeted GLP-1 therapy as a viable HFpEF treatment strategy.
Why it matters
HFpEF has been notoriously difficult to treat — no drug has consistently improved outcomes across all patients. Identifying that the obesity phenotype responds to GLP-1 peptide therapy represents a major shift toward personalized heart failure treatment based on underlying cause.
The numbers in context
Obesity is one of the leading HFpEF phenotypes, with prevalence growing worldwide.
How the study worked
Narrative review with PubMed literature search through April 2024. Examines the pathophysiological links between obesity and HFpEF and synthesizes evidence from key clinical trials (STEP HFpEF, SELECT) and related studies of GLP-1 receptor agonists in heart failure.
Who was studied
Review of obesity-related HFpEF pathogenesis and treatment
What this study cannot tell us
Review article — no original data. Relies primarily on two landmark trials. Long-term safety and durability of benefits with semaglutide in HFpEF not yet established. The obesity phenotype is heterogeneous, and not all obese HFpEF patients may respond similarly.
How to read the evidence
Rated moderate: review synthesizing two high-quality RCTs (STEP HFpEF and SELECT), but no original data or systematic methodology. The underlying evidence is strong.
When this study was published
Published in 2024. Reviews the most current landmark trial data on GLP-1 agonists in heart failure.
The bigger picture
This represents a convergence of two major health trends: the obesity epidemic and the GLP-1 peptide revolution. If heart failure treatment can be personalized by phenotype — with obese patients specifically benefiting from GLP-1 agonists — it could reshape cardiology practice for millions of patients.
Questions still open
- Will dual GIP/GLP-1 agonists like tirzepatide show even greater benefits in obese HFpEF given their more potent weight loss?
- Can the cardiovascular benefits be sustained long-term, or do they diminish if weight is regained?
- How should clinicians identify which obese HFpEF patients will benefit most from GLP-1 therapy?
Common questions
Can semaglutide help with heart failure?
Why is obesity linked to heart failure?
Read the original research
Targeting obesity for therapeutic intervention in heart failure patients.
Expert review of cardiovascular therapy, 22(6), 217-230
Citation
Sato, Ryosuke; von Haehling, Stephan. (2024). Targeting obesity for therapeutic intervention in heart failure patients.. Expert review of cardiovascular therapy, 22(6), 217-230. https://doi.org/10.1080/14779072.2024.2363395